SCHEMBL30795019

SCHEMBL30795019

O=C1c2sc(OCc3cccc(F)c3)nc2CCN1c1cccc(F)c1

nearest known ligand 0.71

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 13/20 0.71
PTGS1 P23219 1/20 0.47
PTGS2 P35354 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2008624 1.00 GRM5 (0.71) GRM5PTGS1PTGS2
SCHEMBL2012544 0.93 GRM5 (0.83) GRM5PTGS1PTGS2
SCHEMBL12980297 0.92 GRM5 (0.64) GRM5PTGS1PTGS2
SCHEMBL30795706 0.92 GRM5 (0.64) GRM5PTGS1PTGS2
SCHEMBL12980043 0.89 GRM5 (0.70) GRM5PTGS1PTGS2
SCHEMBL2014502 0.87 GRM5 (0.66) GRM5PTGS1PTGS2
SCHEMBL2014000 0.83 GRM5 (1.00) GRM5
SCHEMBL2012164 0.81 GRM5 (0.64) GRM5PTGS1PTGS2
SCHEMBL2010619 0.80 GRM5 (0.62) GRM5PTGS1PTGS2
SCHEMBL2013990 0.80 GRM5 (0.75) GRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4584250-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS Biohaven Therapeutics Ltd. (VG) 2025-07-16 EP disclosed
WO-2024054811-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS BIOHAVEN THERAPEUTICS LTD. (VG) 2024-03-14 WO disclosed